Global Psychedelic Drugs Market

Psychedelic Drugs Comprehensive Study by Application (Major Depressive Disorder, Resistant Depression, Panic Disorder, Post-traumatic Stress Disorder, Opiate Addiction, Others), Drug Type (Lysergic Acid Diethylamide (LSD), 3,4-MethylEnedioxyMethamphetamine (Ecstasy), Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Ketamine, Ayahuasca, Salvia, Psilocybin, Others), Route of Administration (Oral, Injectable, Inhalation), Distribution Channel (Direct Retailers, Online Pharmacies, Others), End User (Hospitals, Homecare, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2026

Psychedelic Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Psychedelic Drugs, also known as psychedelics include both classic hallucinogens and dissociative drugs. These drugs are used in the treatment of the major depressive disorder, treatment-resistant depression, panic disorder, and promoting spiritual experiences. These drugs are used experimentally to mimic psychosis and to exert mind control. The increasing scientific researches of psychedelics drugs is expected to boost the market growth in the forecast period.This growth is primarily driven by Increasing Occurrence of Depression and Treatment for Psychedelic Drugs Dependency.

Major Players, such as COMPASS (United Kingdom), The Emmes Company, LLC (United States), Klarisana (United Kingdom), AstraZeneca PLC (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), Dr. Reddy’s Laboratories Ltd (India), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc (United States), Mylan N.V. (United States), Merck & Co., Inc (United States), Alkermes (Ireland), Allergan plc (Ireland) and H. Lundbeck A/S (Denmark) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In September 2019, Johns Hopkins Medicine launched a new research center named Center for Psychedelic and Consciousness Research, with USD 17 million with aim to offer “psychedelic medicine”.

Market Drivers
  • Increasing Occurrence of Depression
  • Treatment for Psychedelic Drugs Dependency

Market Trend

Restraints
  • Preference of Non-Therapeutics Therapies

Opportunities
Changing Life Style and Demand for Enhanced Life Quality and Growing Acceptance of Psychedelic Drugs for Treating Depression
Challenges
Poor Efficacy and Safety Profile Of Existing Intervention

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Psychedelic Drugs Study Sheds Light on
— The Psychedelic Drugs Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Psychedelic Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Psychedelic Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Major Depressive Disorder
  • Resistant Depression
  • Panic Disorder
  • Post-traumatic Stress Disorder
  • Opiate Addiction
  • Others
By Drug Type
  • Lysergic Acid Diethylamide (LSD)
  • 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
  • Phencyclidine
  • Gamma Hydroxybutyric Acid (GHB)
  • Ketamine
  • Ayahuasca
  • Salvia
  • Psilocybin
  • Others

By Route of Administration
  • Oral
  • Injectable
  • Inhalation

By Distribution Channel
  • Direct Retailers
  • Online Pharmacies
  • Others

By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Occurrence of Depression
      • 3.2.2. Treatment for Psychedelic Drugs Dependency
    • 3.3. Market Challenges
      • 3.3.1. Poor Efficacy and Safety Profile Of Existing Intervention
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Psychedelic Drugs, by Application, Drug Type, Route of Administration, Distribution Channel, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Psychedelic Drugs (Value)
      • 5.2.1. Global Psychedelic Drugs by: Application (Value)
        • 5.2.1.1. Major Depressive Disorder
        • 5.2.1.2. Resistant Depression
        • 5.2.1.3. Panic Disorder
        • 5.2.1.4. Post-traumatic Stress Disorder
        • 5.2.1.5. Opiate Addiction
        • 5.2.1.6. Others
      • 5.2.2. Global Psychedelic Drugs by: Drug Type (Value)
        • 5.2.2.1. Lysergic Acid Diethylamide (LSD)
        • 5.2.2.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
        • 5.2.2.3. Phencyclidine
        • 5.2.2.4. Gamma Hydroxybutyric Acid (GHB)
        • 5.2.2.5. Ketamine
        • 5.2.2.6. Ayahuasca
        • 5.2.2.7. Salvia
        • 5.2.2.8. Psilocybin
        • 5.2.2.9. Others
      • 5.2.3. Global Psychedelic Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injectable
        • 5.2.3.3. Inhalation
      • 5.2.4. Global Psychedelic Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Direct Retailers
        • 5.2.4.2. Online Pharmacies
        • 5.2.4.3. Others
      • 5.2.5. Global Psychedelic Drugs by: End User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Homecare
        • 5.2.5.3. Specialty Clinics
        • 5.2.5.4. Others
      • 5.2.6. Global Psychedelic Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Australia
          • 5.2.6.2.6. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Psychedelic Drugs (Volume)
      • 5.3.1. Global Psychedelic Drugs by: Application (Volume)
        • 5.3.1.1. Major Depressive Disorder
        • 5.3.1.2. Resistant Depression
        • 5.3.1.3. Panic Disorder
        • 5.3.1.4. Post-traumatic Stress Disorder
        • 5.3.1.5. Opiate Addiction
        • 5.3.1.6. Others
      • 5.3.2. Global Psychedelic Drugs by: Drug Type (Volume)
        • 5.3.2.1. Lysergic Acid Diethylamide (LSD)
        • 5.3.2.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
        • 5.3.2.3. Phencyclidine
        • 5.3.2.4. Gamma Hydroxybutyric Acid (GHB)
        • 5.3.2.5. Ketamine
        • 5.3.2.6. Ayahuasca
        • 5.3.2.7. Salvia
        • 5.3.2.8. Psilocybin
        • 5.3.2.9. Others
      • 5.3.3. Global Psychedelic Drugs by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injectable
        • 5.3.3.3. Inhalation
      • 5.3.4. Global Psychedelic Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Direct Retailers
        • 5.3.4.2. Online Pharmacies
        • 5.3.4.3. Others
      • 5.3.5. Global Psychedelic Drugs by: End User (Volume)
        • 5.3.5.1. Hospitals
        • 5.3.5.2. Homecare
        • 5.3.5.3. Specialty Clinics
        • 5.3.5.4. Others
      • 5.3.6. Global Psychedelic Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Australia
          • 5.3.6.2.6. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Psychedelic Drugs (Price)
  • 6. Psychedelic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. COMPASS (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. The Emmes Company, LLC (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Klarisana (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca PLC (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dr. Reddy’s Laboratories Ltd (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mylan N.V. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co., Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Alkermes (Ireland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Allergan plc (Ireland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. H. Lundbeck A/S (Denmark)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Psychedelic Drugs Sale, by Application, Drug Type, Route of Administration, Distribution Channel, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Psychedelic Drugs (Value)
      • 7.2.1. Global Psychedelic Drugs by: Application (Value)
        • 7.2.1.1. Major Depressive Disorder
        • 7.2.1.2. Resistant Depression
        • 7.2.1.3. Panic Disorder
        • 7.2.1.4. Post-traumatic Stress Disorder
        • 7.2.1.5. Opiate Addiction
        • 7.2.1.6. Others
      • 7.2.2. Global Psychedelic Drugs by: Drug Type (Value)
        • 7.2.2.1. Lysergic Acid Diethylamide (LSD)
        • 7.2.2.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
        • 7.2.2.3. Phencyclidine
        • 7.2.2.4. Gamma Hydroxybutyric Acid (GHB)
        • 7.2.2.5. Ketamine
        • 7.2.2.6. Ayahuasca
        • 7.2.2.7. Salvia
        • 7.2.2.8. Psilocybin
        • 7.2.2.9. Others
      • 7.2.3. Global Psychedelic Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injectable
        • 7.2.3.3. Inhalation
      • 7.2.4. Global Psychedelic Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Direct Retailers
        • 7.2.4.2. Online Pharmacies
        • 7.2.4.3. Others
      • 7.2.5. Global Psychedelic Drugs by: End User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Homecare
        • 7.2.5.3. Specialty Clinics
        • 7.2.5.4. Others
      • 7.2.6. Global Psychedelic Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Australia
          • 7.2.6.2.6. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Psychedelic Drugs (Volume)
      • 7.3.1. Global Psychedelic Drugs by: Application (Volume)
        • 7.3.1.1. Major Depressive Disorder
        • 7.3.1.2. Resistant Depression
        • 7.3.1.3. Panic Disorder
        • 7.3.1.4. Post-traumatic Stress Disorder
        • 7.3.1.5. Opiate Addiction
        • 7.3.1.6. Others
      • 7.3.2. Global Psychedelic Drugs by: Drug Type (Volume)
        • 7.3.2.1. Lysergic Acid Diethylamide (LSD)
        • 7.3.2.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
        • 7.3.2.3. Phencyclidine
        • 7.3.2.4. Gamma Hydroxybutyric Acid (GHB)
        • 7.3.2.5. Ketamine
        • 7.3.2.6. Ayahuasca
        • 7.3.2.7. Salvia
        • 7.3.2.8. Psilocybin
        • 7.3.2.9. Others
      • 7.3.3. Global Psychedelic Drugs by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injectable
        • 7.3.3.3. Inhalation
      • 7.3.4. Global Psychedelic Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Direct Retailers
        • 7.3.4.2. Online Pharmacies
        • 7.3.4.3. Others
      • 7.3.5. Global Psychedelic Drugs by: End User (Volume)
        • 7.3.5.1. Hospitals
        • 7.3.5.2. Homecare
        • 7.3.5.3. Specialty Clinics
        • 7.3.5.4. Others
      • 7.3.6. Global Psychedelic Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Australia
          • 7.3.6.2.6. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Psychedelic Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Psychedelic Drugs: by Application(USD Million)
  • Table 2. Psychedelic Drugs Major Depressive Disorder , by Region USD Million (2015-2020)
  • Table 3. Psychedelic Drugs Resistant Depression , by Region USD Million (2015-2020)
  • Table 4. Psychedelic Drugs Panic Disorder , by Region USD Million (2015-2020)
  • Table 5. Psychedelic Drugs Post-traumatic Stress Disorder , by Region USD Million (2015-2020)
  • Table 6. Psychedelic Drugs Opiate Addiction , by Region USD Million (2015-2020)
  • Table 7. Psychedelic Drugs Others , by Region USD Million (2015-2020)
  • Table 8. Psychedelic Drugs: by Drug Type(USD Million)
  • Table 9. Psychedelic Drugs Lysergic Acid Diethylamide (LSD) , by Region USD Million (2015-2020)
  • Table 10. Psychedelic Drugs 3,4-MethylEnedioxyMethamphetamine (Ecstasy) , by Region USD Million (2015-2020)
  • Table 11. Psychedelic Drugs Phencyclidine , by Region USD Million (2015-2020)
  • Table 12. Psychedelic Drugs Gamma Hydroxybutyric Acid (GHB) , by Region USD Million (2015-2020)
  • Table 13. Psychedelic Drugs Ketamine , by Region USD Million (2015-2020)
  • Table 14. Psychedelic Drugs Ayahuasca , by Region USD Million (2015-2020)
  • Table 15. Psychedelic Drugs Salvia , by Region USD Million (2015-2020)
  • Table 16. Psychedelic Drugs Psilocybin , by Region USD Million (2015-2020)
  • Table 17. Psychedelic Drugs Others , by Region USD Million (2015-2020)
  • Table 18. Psychedelic Drugs: by Route of Administration(USD Million)
  • Table 19. Psychedelic Drugs Oral , by Region USD Million (2015-2020)
  • Table 20. Psychedelic Drugs Injectable , by Region USD Million (2015-2020)
  • Table 21. Psychedelic Drugs Inhalation , by Region USD Million (2015-2020)
  • Table 22. Psychedelic Drugs: by Distribution Channel(USD Million)
  • Table 23. Psychedelic Drugs Direct Retailers , by Region USD Million (2015-2020)
  • Table 24. Psychedelic Drugs Online Pharmacies , by Region USD Million (2015-2020)
  • Table 25. Psychedelic Drugs Others , by Region USD Million (2015-2020)
  • Table 26. Psychedelic Drugs: by End User(USD Million)
  • Table 27. Psychedelic Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 28. Psychedelic Drugs Homecare , by Region USD Million (2015-2020)
  • Table 29. Psychedelic Drugs Specialty Clinics , by Region USD Million (2015-2020)
  • Table 30. Psychedelic Drugs Others , by Region USD Million (2015-2020)
  • Table 31. South America Psychedelic Drugs, by Country USD Million (2015-2020)
  • Table 32. South America Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 33. South America Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 34. South America Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 35. South America Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 36. South America Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 37. Brazil Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 38. Brazil Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 39. Brazil Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 40. Brazil Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 41. Brazil Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 42. Argentina Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 43. Argentina Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 44. Argentina Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 45. Argentina Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 46. Argentina Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 47. Rest of South America Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 48. Rest of South America Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 49. Rest of South America Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 50. Rest of South America Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. Rest of South America Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 52. Asia Pacific Psychedelic Drugs, by Country USD Million (2015-2020)
  • Table 53. Asia Pacific Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 54. Asia Pacific Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 55. Asia Pacific Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 56. Asia Pacific Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 57. Asia Pacific Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 58. China Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 59. China Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 60. China Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 61. China Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 62. China Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 63. Japan Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 64. Japan Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 65. Japan Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 66. Japan Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 67. Japan Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 68. India Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 69. India Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 70. India Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 71. India Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 72. India Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 73. South Korea Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 74. South Korea Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 75. South Korea Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 76. South Korea Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 77. South Korea Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 78. Australia Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 79. Australia Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 80. Australia Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 81. Australia Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 82. Australia Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 86. Rest of Asia-Pacific Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 87. Rest of Asia-Pacific Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 88. Europe Psychedelic Drugs, by Country USD Million (2015-2020)
  • Table 89. Europe Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 90. Europe Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 91. Europe Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 92. Europe Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 93. Europe Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 94. Germany Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 95. Germany Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 96. Germany Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 97. Germany Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 98. Germany Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 99. France Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 100. France Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 101. France Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 102. France Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 103. France Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 104. Italy Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 105. Italy Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 106. Italy Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 107. Italy Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 108. Italy Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 109. United Kingdom Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 110. United Kingdom Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 111. United Kingdom Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 112. United Kingdom Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 113. United Kingdom Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 114. Netherlands Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 115. Netherlands Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 116. Netherlands Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 117. Netherlands Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 118. Netherlands Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 119. Rest of Europe Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 120. Rest of Europe Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 121. Rest of Europe Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 122. Rest of Europe Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 123. Rest of Europe Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 124. MEA Psychedelic Drugs, by Country USD Million (2015-2020)
  • Table 125. MEA Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 126. MEA Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 127. MEA Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 128. MEA Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 129. MEA Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 130. Middle East Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 131. Middle East Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 132. Middle East Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 133. Middle East Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 134. Middle East Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 135. Africa Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 136. Africa Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 137. Africa Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 138. Africa Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 139. Africa Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 140. North America Psychedelic Drugs, by Country USD Million (2015-2020)
  • Table 141. North America Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 142. North America Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 143. North America Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 144. North America Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 145. North America Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 146. United States Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 147. United States Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 148. United States Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 149. United States Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 150. United States Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 151. Canada Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 152. Canada Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 153. Canada Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 154. Canada Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 155. Canada Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 156. Mexico Psychedelic Drugs, by Application USD Million (2015-2020)
  • Table 157. Mexico Psychedelic Drugs, by Drug Type USD Million (2015-2020)
  • Table 158. Mexico Psychedelic Drugs, by Route of Administration USD Million (2015-2020)
  • Table 159. Mexico Psychedelic Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 160. Mexico Psychedelic Drugs, by End User USD Million (2015-2020)
  • Table 161. Psychedelic Drugs Sales: by Application(K Tons)
  • Table 162. Psychedelic Drugs Sales Major Depressive Disorder , by Region K Tons (2015-2020)
  • Table 163. Psychedelic Drugs Sales Resistant Depression , by Region K Tons (2015-2020)
  • Table 164. Psychedelic Drugs Sales Panic Disorder , by Region K Tons (2015-2020)
  • Table 165. Psychedelic Drugs Sales Post-traumatic Stress Disorder , by Region K Tons (2015-2020)
  • Table 166. Psychedelic Drugs Sales Opiate Addiction , by Region K Tons (2015-2020)
  • Table 167. Psychedelic Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 168. Psychedelic Drugs Sales: by Drug Type(K Tons)
  • Table 169. Psychedelic Drugs Sales Lysergic Acid Diethylamide (LSD) , by Region K Tons (2015-2020)
  • Table 170. Psychedelic Drugs Sales 3,4-MethylEnedioxyMethamphetamine (Ecstasy) , by Region K Tons (2015-2020)
  • Table 171. Psychedelic Drugs Sales Phencyclidine , by Region K Tons (2015-2020)
  • Table 172. Psychedelic Drugs Sales Gamma Hydroxybutyric Acid (GHB) , by Region K Tons (2015-2020)
  • Table 173. Psychedelic Drugs Sales Ketamine , by Region K Tons (2015-2020)
  • Table 174. Psychedelic Drugs Sales Ayahuasca , by Region K Tons (2015-2020)
  • Table 175. Psychedelic Drugs Sales Salvia , by Region K Tons (2015-2020)
  • Table 176. Psychedelic Drugs Sales Psilocybin , by Region K Tons (2015-2020)
  • Table 177. Psychedelic Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 178. Psychedelic Drugs Sales: by Route of Administration(K Tons)
  • Table 179. Psychedelic Drugs Sales Oral , by Region K Tons (2015-2020)
  • Table 180. Psychedelic Drugs Sales Injectable , by Region K Tons (2015-2020)
  • Table 181. Psychedelic Drugs Sales Inhalation , by Region K Tons (2015-2020)
  • Table 182. Psychedelic Drugs Sales: by Distribution Channel(K Tons)
  • Table 183. Psychedelic Drugs Sales Direct Retailers , by Region K Tons (2015-2020)
  • Table 184. Psychedelic Drugs Sales Online Pharmacies , by Region K Tons (2015-2020)
  • Table 185. Psychedelic Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 186. Psychedelic Drugs Sales: by End User(K Tons)
  • Table 187. Psychedelic Drugs Sales Hospitals , by Region K Tons (2015-2020)
  • Table 188. Psychedelic Drugs Sales Homecare , by Region K Tons (2015-2020)
  • Table 189. Psychedelic Drugs Sales Specialty Clinics , by Region K Tons (2015-2020)
  • Table 190. Psychedelic Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 191. South America Psychedelic Drugs Sales, by Country K Tons (2015-2020)
  • Table 192. South America Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 193. South America Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 194. South America Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 195. South America Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 196. South America Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 197. Brazil Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 198. Brazil Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 199. Brazil Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 200. Brazil Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 201. Brazil Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 202. Argentina Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 203. Argentina Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 204. Argentina Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 205. Argentina Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 206. Argentina Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 207. Rest of South America Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 208. Rest of South America Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 209. Rest of South America Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 210. Rest of South America Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 211. Rest of South America Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 212. Asia Pacific Psychedelic Drugs Sales, by Country K Tons (2015-2020)
  • Table 213. Asia Pacific Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 214. Asia Pacific Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 215. Asia Pacific Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 216. Asia Pacific Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 217. Asia Pacific Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 218. China Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 219. China Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 220. China Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 221. China Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 222. China Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 223. Japan Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 224. Japan Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 225. Japan Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 226. Japan Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 227. Japan Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 228. India Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 229. India Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 230. India Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 231. India Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 232. India Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 233. South Korea Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 234. South Korea Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 235. South Korea Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 236. South Korea Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 237. South Korea Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 238. Australia Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 239. Australia Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 240. Australia Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 241. Australia Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 242. Australia Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 243. Rest of Asia-Pacific Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 244. Rest of Asia-Pacific Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 245. Rest of Asia-Pacific Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 246. Rest of Asia-Pacific Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 247. Rest of Asia-Pacific Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 248. Europe Psychedelic Drugs Sales, by Country K Tons (2015-2020)
  • Table 249. Europe Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 250. Europe Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 251. Europe Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 252. Europe Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 253. Europe Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 254. Germany Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 255. Germany Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 256. Germany Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 257. Germany Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 258. Germany Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 259. France Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 260. France Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 261. France Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 262. France Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 263. France Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 264. Italy Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 265. Italy Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 266. Italy Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 267. Italy Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 268. Italy Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 269. United Kingdom Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 270. United Kingdom Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 271. United Kingdom Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 272. United Kingdom Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 273. United Kingdom Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 274. Netherlands Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 275. Netherlands Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 276. Netherlands Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 277. Netherlands Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 278. Netherlands Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 279. Rest of Europe Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 280. Rest of Europe Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 281. Rest of Europe Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 282. Rest of Europe Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 283. Rest of Europe Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 284. MEA Psychedelic Drugs Sales, by Country K Tons (2015-2020)
  • Table 285. MEA Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 286. MEA Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 287. MEA Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 288. MEA Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 289. MEA Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 290. Middle East Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 291. Middle East Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 292. Middle East Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 293. Middle East Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 294. Middle East Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 295. Africa Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 296. Africa Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 297. Africa Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 298. Africa Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 299. Africa Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 300. North America Psychedelic Drugs Sales, by Country K Tons (2015-2020)
  • Table 301. North America Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 302. North America Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 303. North America Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 304. North America Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 305. North America Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 306. United States Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 307. United States Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 308. United States Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 309. United States Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 310. United States Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 311. Canada Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 312. Canada Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 313. Canada Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 314. Canada Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 315. Canada Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 316. Mexico Psychedelic Drugs Sales, by Application K Tons (2015-2020)
  • Table 317. Mexico Psychedelic Drugs Sales, by Drug Type K Tons (2015-2020)
  • Table 318. Mexico Psychedelic Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 319. Mexico Psychedelic Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 320. Mexico Psychedelic Drugs Sales, by End User K Tons (2015-2020)
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Psychedelic Drugs: by Application(USD Million)
  • Table 335. Psychedelic Drugs Major Depressive Disorder , by Region USD Million (2021-2026)
  • Table 336. Psychedelic Drugs Resistant Depression , by Region USD Million (2021-2026)
  • Table 337. Psychedelic Drugs Panic Disorder , by Region USD Million (2021-2026)
  • Table 338. Psychedelic Drugs Post-traumatic Stress Disorder , by Region USD Million (2021-2026)
  • Table 339. Psychedelic Drugs Opiate Addiction , by Region USD Million (2021-2026)
  • Table 340. Psychedelic Drugs Others , by Region USD Million (2021-2026)
  • Table 341. Psychedelic Drugs: by Drug Type(USD Million)
  • Table 342. Psychedelic Drugs Lysergic Acid Diethylamide (LSD) , by Region USD Million (2021-2026)
  • Table 343. Psychedelic Drugs 3,4-MethylEnedioxyMethamphetamine (Ecstasy) , by Region USD Million (2021-2026)
  • Table 344. Psychedelic Drugs Phencyclidine , by Region USD Million (2021-2026)
  • Table 345. Psychedelic Drugs Gamma Hydroxybutyric Acid (GHB) , by Region USD Million (2021-2026)
  • Table 346. Psychedelic Drugs Ketamine , by Region USD Million (2021-2026)
  • Table 347. Psychedelic Drugs Ayahuasca , by Region USD Million (2021-2026)
  • Table 348. Psychedelic Drugs Salvia , by Region USD Million (2021-2026)
  • Table 349. Psychedelic Drugs Psilocybin , by Region USD Million (2021-2026)
  • Table 350. Psychedelic Drugs Others , by Region USD Million (2021-2026)
  • Table 351. Psychedelic Drugs: by Route of Administration(USD Million)
  • Table 352. Psychedelic Drugs Oral , by Region USD Million (2021-2026)
  • Table 353. Psychedelic Drugs Injectable , by Region USD Million (2021-2026)
  • Table 354. Psychedelic Drugs Inhalation , by Region USD Million (2021-2026)
  • Table 355. Psychedelic Drugs: by Distribution Channel(USD Million)
  • Table 356. Psychedelic Drugs Direct Retailers , by Region USD Million (2021-2026)
  • Table 357. Psychedelic Drugs Online Pharmacies , by Region USD Million (2021-2026)
  • Table 358. Psychedelic Drugs Others , by Region USD Million (2021-2026)
  • Table 359. Psychedelic Drugs: by End User(USD Million)
  • Table 360. Psychedelic Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 361. Psychedelic Drugs Homecare , by Region USD Million (2021-2026)
  • Table 362. Psychedelic Drugs Specialty Clinics , by Region USD Million (2021-2026)
  • Table 363. Psychedelic Drugs Others , by Region USD Million (2021-2026)
  • Table 364. South America Psychedelic Drugs, by Country USD Million (2021-2026)
  • Table 365. South America Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 366. South America Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 367. South America Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 368. South America Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 369. South America Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 370. Brazil Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 371. Brazil Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 372. Brazil Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 373. Brazil Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 374. Brazil Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 375. Argentina Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 376. Argentina Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 377. Argentina Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 378. Argentina Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 379. Argentina Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 380. Rest of South America Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 381. Rest of South America Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 382. Rest of South America Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 383. Rest of South America Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 384. Rest of South America Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 385. Asia Pacific Psychedelic Drugs, by Country USD Million (2021-2026)
  • Table 386. Asia Pacific Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 387. Asia Pacific Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 388. Asia Pacific Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 389. Asia Pacific Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 390. Asia Pacific Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 391. China Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 392. China Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 393. China Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 394. China Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 395. China Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 396. Japan Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 397. Japan Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 398. Japan Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 399. Japan Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 400. Japan Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 401. India Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 402. India Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 403. India Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 404. India Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 405. India Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 406. South Korea Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 407. South Korea Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 408. South Korea Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 409. South Korea Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 410. South Korea Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 411. Australia Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 412. Australia Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 413. Australia Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 414. Australia Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 415. Australia Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 416. Rest of Asia-Pacific Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 417. Rest of Asia-Pacific Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 418. Rest of Asia-Pacific Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 419. Rest of Asia-Pacific Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 420. Rest of Asia-Pacific Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 421. Europe Psychedelic Drugs, by Country USD Million (2021-2026)
  • Table 422. Europe Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 423. Europe Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 424. Europe Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 425. Europe Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 426. Europe Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 427. Germany Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 428. Germany Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 429. Germany Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 430. Germany Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 431. Germany Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 432. France Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 433. France Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 434. France Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 435. France Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 436. France Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 437. Italy Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 438. Italy Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 439. Italy Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 440. Italy Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 441. Italy Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 442. United Kingdom Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 443. United Kingdom Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 444. United Kingdom Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 445. United Kingdom Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 446. United Kingdom Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 447. Netherlands Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 448. Netherlands Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 449. Netherlands Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 450. Netherlands Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 451. Netherlands Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 452. Rest of Europe Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 453. Rest of Europe Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 454. Rest of Europe Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 455. Rest of Europe Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 456. Rest of Europe Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 457. MEA Psychedelic Drugs, by Country USD Million (2021-2026)
  • Table 458. MEA Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 459. MEA Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 460. MEA Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 461. MEA Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 462. MEA Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 463. Middle East Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 464. Middle East Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 465. Middle East Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 466. Middle East Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 467. Middle East Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 468. Africa Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 469. Africa Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 470. Africa Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 471. Africa Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 472. Africa Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 473. North America Psychedelic Drugs, by Country USD Million (2021-2026)
  • Table 474. North America Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 475. North America Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 476. North America Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 477. North America Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 478. North America Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 479. United States Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 480. United States Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 481. United States Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 482. United States Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 483. United States Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 484. Canada Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 485. Canada Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 486. Canada Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 487. Canada Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 488. Canada Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 489. Mexico Psychedelic Drugs, by Application USD Million (2021-2026)
  • Table 490. Mexico Psychedelic Drugs, by Drug Type USD Million (2021-2026)
  • Table 491. Mexico Psychedelic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 492. Mexico Psychedelic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 493. Mexico Psychedelic Drugs, by End User USD Million (2021-2026)
  • Table 494. Psychedelic Drugs Sales: by Application(K Tons)
  • Table 495. Psychedelic Drugs Sales Major Depressive Disorder , by Region K Tons (2021-2026)
  • Table 496. Psychedelic Drugs Sales Resistant Depression , by Region K Tons (2021-2026)
  • Table 497. Psychedelic Drugs Sales Panic Disorder , by Region K Tons (2021-2026)
  • Table 498. Psychedelic Drugs Sales Post-traumatic Stress Disorder , by Region K Tons (2021-2026)
  • Table 499. Psychedelic Drugs Sales Opiate Addiction , by Region K Tons (2021-2026)
  • Table 500. Psychedelic Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 501. Psychedelic Drugs Sales: by Drug Type(K Tons)
  • Table 502. Psychedelic Drugs Sales Lysergic Acid Diethylamide (LSD) , by Region K Tons (2021-2026)
  • Table 503. Psychedelic Drugs Sales 3,4-MethylEnedioxyMethamphetamine (Ecstasy) , by Region K Tons (2021-2026)
  • Table 504. Psychedelic Drugs Sales Phencyclidine , by Region K Tons (2021-2026)
  • Table 505. Psychedelic Drugs Sales Gamma Hydroxybutyric Acid (GHB) , by Region K Tons (2021-2026)
  • Table 506. Psychedelic Drugs Sales Ketamine , by Region K Tons (2021-2026)
  • Table 507. Psychedelic Drugs Sales Ayahuasca , by Region K Tons (2021-2026)
  • Table 508. Psychedelic Drugs Sales Salvia , by Region K Tons (2021-2026)
  • Table 509. Psychedelic Drugs Sales Psilocybin , by Region K Tons (2021-2026)
  • Table 510. Psychedelic Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 511. Psychedelic Drugs Sales: by Route of Administration(K Tons)
  • Table 512. Psychedelic Drugs Sales Oral , by Region K Tons (2021-2026)
  • Table 513. Psychedelic Drugs Sales Injectable , by Region K Tons (2021-2026)
  • Table 514. Psychedelic Drugs Sales Inhalation , by Region K Tons (2021-2026)
  • Table 515. Psychedelic Drugs Sales: by Distribution Channel(K Tons)
  • Table 516. Psychedelic Drugs Sales Direct Retailers , by Region K Tons (2021-2026)
  • Table 517. Psychedelic Drugs Sales Online Pharmacies , by Region K Tons (2021-2026)
  • Table 518. Psychedelic Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 519. Psychedelic Drugs Sales: by End User(K Tons)
  • Table 520. Psychedelic Drugs Sales Hospitals , by Region K Tons (2021-2026)
  • Table 521. Psychedelic Drugs Sales Homecare , by Region K Tons (2021-2026)
  • Table 522. Psychedelic Drugs Sales Specialty Clinics , by Region K Tons (2021-2026)
  • Table 523. Psychedelic Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 524. South America Psychedelic Drugs Sales, by Country K Tons (2021-2026)
  • Table 525. South America Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 526. South America Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 527. South America Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 528. South America Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 529. South America Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 530. Brazil Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 531. Brazil Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 532. Brazil Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 533. Brazil Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 534. Brazil Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 535. Argentina Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 536. Argentina Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 537. Argentina Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 538. Argentina Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 539. Argentina Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 540. Rest of South America Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 541. Rest of South America Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 542. Rest of South America Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 543. Rest of South America Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 544. Rest of South America Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 545. Asia Pacific Psychedelic Drugs Sales, by Country K Tons (2021-2026)
  • Table 546. Asia Pacific Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 547. Asia Pacific Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 548. Asia Pacific Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 549. Asia Pacific Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 550. Asia Pacific Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 551. China Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 552. China Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 553. China Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 554. China Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 555. China Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 556. Japan Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 557. Japan Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 558. Japan Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 559. Japan Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 560. Japan Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 561. India Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 562. India Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 563. India Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 564. India Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 565. India Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 566. South Korea Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 567. South Korea Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 568. South Korea Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 569. South Korea Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 570. South Korea Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 571. Australia Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 572. Australia Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 573. Australia Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 574. Australia Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 575. Australia Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 576. Rest of Asia-Pacific Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 577. Rest of Asia-Pacific Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 578. Rest of Asia-Pacific Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 579. Rest of Asia-Pacific Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 580. Rest of Asia-Pacific Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 581. Europe Psychedelic Drugs Sales, by Country K Tons (2021-2026)
  • Table 582. Europe Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 583. Europe Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 584. Europe Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 585. Europe Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 586. Europe Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 587. Germany Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 588. Germany Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 589. Germany Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 590. Germany Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 591. Germany Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 592. France Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 593. France Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 594. France Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 595. France Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 596. France Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 597. Italy Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 598. Italy Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 599. Italy Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 600. Italy Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 601. Italy Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 602. United Kingdom Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 603. United Kingdom Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 604. United Kingdom Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 605. United Kingdom Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 606. United Kingdom Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 607. Netherlands Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 608. Netherlands Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 609. Netherlands Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 610. Netherlands Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 611. Netherlands Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 612. Rest of Europe Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 613. Rest of Europe Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 614. Rest of Europe Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 615. Rest of Europe Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 616. Rest of Europe Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 617. MEA Psychedelic Drugs Sales, by Country K Tons (2021-2026)
  • Table 618. MEA Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 619. MEA Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 620. MEA Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 621. MEA Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 622. MEA Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 623. Middle East Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 624. Middle East Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 625. Middle East Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 626. Middle East Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 627. Middle East Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 628. Africa Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 629. Africa Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 630. Africa Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 631. Africa Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 632. Africa Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 633. North America Psychedelic Drugs Sales, by Country K Tons (2021-2026)
  • Table 634. North America Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 635. North America Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 636. North America Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 637. North America Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 638. North America Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 639. United States Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 640. United States Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 641. United States Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 642. United States Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 643. United States Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 644. Canada Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 645. Canada Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 646. Canada Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 647. Canada Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 648. Canada Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 649. Mexico Psychedelic Drugs Sales, by Application K Tons (2021-2026)
  • Table 650. Mexico Psychedelic Drugs Sales, by Drug Type K Tons (2021-2026)
  • Table 651. Mexico Psychedelic Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 652. Mexico Psychedelic Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 653. Mexico Psychedelic Drugs Sales, by End User K Tons (2021-2026)
  • Table 654. Research Programs/Design for This Report
  • Table 655. Key Data Information from Secondary Sources
  • Table 656. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Psychedelic Drugs: by Application USD Million (2015-2020)
  • Figure 5. Global Psychedelic Drugs: by Drug Type USD Million (2015-2020)
  • Figure 6. Global Psychedelic Drugs: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Psychedelic Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Psychedelic Drugs: by End User USD Million (2015-2020)
  • Figure 9. South America Psychedelic Drugs Share (%), by Country
  • Figure 10. Asia Pacific Psychedelic Drugs Share (%), by Country
  • Figure 11. Europe Psychedelic Drugs Share (%), by Country
  • Figure 12. MEA Psychedelic Drugs Share (%), by Country
  • Figure 13. North America Psychedelic Drugs Share (%), by Country
  • Figure 14. Global Psychedelic Drugs: by Application K Tons (2015-2020)
  • Figure 15. Global Psychedelic Drugs: by Drug Type K Tons (2015-2020)
  • Figure 16. Global Psychedelic Drugs: by Route of Administration K Tons (2015-2020)
  • Figure 17. Global Psychedelic Drugs: by Distribution Channel K Tons (2015-2020)
  • Figure 18. Global Psychedelic Drugs: by End User K Tons (2015-2020)
  • Figure 19. South America Psychedelic Drugs Share (%), by Country
  • Figure 20. Asia Pacific Psychedelic Drugs Share (%), by Country
  • Figure 21. Europe Psychedelic Drugs Share (%), by Country
  • Figure 22. MEA Psychedelic Drugs Share (%), by Country
  • Figure 23. North America Psychedelic Drugs Share (%), by Country
  • Figure 24. Global Psychedelic Drugs share by Players 2020 (%)
  • Figure 25. Global Psychedelic Drugs share by Players (Top 3) 2020(%)
  • Figure 26. Global Psychedelic Drugs share by Players (Top 5) 2020(%)
  • Figure 27. BCG Matrix for key Companies
  • Figure 28. COMPASS (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. COMPASS (United Kingdom) Revenue: by Geography 2020
  • Figure 30. The Emmes Company, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 31. The Emmes Company, LLC (United States) Revenue: by Geography 2020
  • Figure 32. Klarisana (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Klarisana (United Kingdom) Revenue: by Geography 2020
  • Figure 34. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 36. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 38. Dr. Reddy’s Laboratories Ltd (India) Revenue, Net Income and Gross profit
  • Figure 39. Dr. Reddy’s Laboratories Ltd (India) Revenue: by Geography 2020
  • Figure 40. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 41. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 42. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 43. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 44. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 45. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 46. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 47. Merck & Co., Inc (United States) Revenue: by Geography 2020
  • Figure 48. Alkermes (Ireland) Revenue, Net Income and Gross profit
  • Figure 49. Alkermes (Ireland) Revenue: by Geography 2020
  • Figure 50. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 51. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 52. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 53. H. Lundbeck A/S (Denmark) Revenue: by Geography 2020
  • Figure 54. Global Psychedelic Drugs: by Application USD Million (2021-2026)
  • Figure 55. Global Psychedelic Drugs: by Drug Type USD Million (2021-2026)
  • Figure 56. Global Psychedelic Drugs: by Route of Administration USD Million (2021-2026)
  • Figure 57. Global Psychedelic Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 58. Global Psychedelic Drugs: by End User USD Million (2021-2026)
  • Figure 59. South America Psychedelic Drugs Share (%), by Country
  • Figure 60. Asia Pacific Psychedelic Drugs Share (%), by Country
  • Figure 61. Europe Psychedelic Drugs Share (%), by Country
  • Figure 62. MEA Psychedelic Drugs Share (%), by Country
  • Figure 63. North America Psychedelic Drugs Share (%), by Country
  • Figure 64. Global Psychedelic Drugs: by Application K Tons (2021-2026)
  • Figure 65. Global Psychedelic Drugs: by Drug Type K Tons (2021-2026)
  • Figure 66. Global Psychedelic Drugs: by Route of Administration K Tons (2021-2026)
  • Figure 67. Global Psychedelic Drugs: by Distribution Channel K Tons (2021-2026)
  • Figure 68. Global Psychedelic Drugs: by End User K Tons (2021-2026)
  • Figure 69. South America Psychedelic Drugs Share (%), by Country
  • Figure 70. Asia Pacific Psychedelic Drugs Share (%), by Country
  • Figure 71. Europe Psychedelic Drugs Share (%), by Country
  • Figure 72. MEA Psychedelic Drugs Share (%), by Country
  • Figure 73. North America Psychedelic Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • COMPASS (United Kingdom)
  • The Emmes Company, LLC (United States)
  • Klarisana (United Kingdom)
  • AstraZeneca PLC (United Kingdom)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Dr. Reddy’s Laboratories Ltd (India)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Pfizer Inc (United States)
  • Mylan N.V. (United States)
  • Merck & Co., Inc (United States)
  • Alkermes (Ireland)
  • Allergan plc (Ireland)
  • H. Lundbeck A/S (Denmark)
Select User Access Type

Key Highlights of Report


Jan 2022 212 Pages 77 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Psychedelic Drugs Market Quantitative research analysis
Global Psychedelic Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Psychedelic Drugs Market are COMPASS (United Kingdom), The Emmes Company, LLC (United States), Klarisana (United Kingdom), AstraZeneca PLC (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), Dr. Reddy’s Laboratories Ltd (India), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc (United States), Mylan N.V. (United States), Merck & Co., Inc (United States), Alkermes (Ireland), Allergan plc (Ireland) and H. Lundbeck A/S (Denmark) etc.
Psychedelic Drugs, also known as psychedelics include both classic hallucinogens and dissociative drugs. These drugs are used in the treatment of the major depressive disorder, treatment-resistant depression, panic disorder, and promoting spiritual experiences. These drugs are used experimentally to mimic psychosis and to exert mind control. The increasing scientific researches of psychedelics drugs is expected to boost the market growth in the forecast period.

Know More About Global Psychedelic Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Olanzapine Comprehensive Study by Type (Patent, Generics), Application (Schizophrenia, Bipolar Disorder, Other), Product Type (Tablet, Injection), Sales Channel (Online Pharmacy, Hospital Pharmacy, R...
$ 3350
Cephalexin Comprehensive Study by Type (Injection, Oral), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region -...
$ 3500
Mebendazole Comprehensive Study by Type (≥98%, ≥99%), End users (Below 2 Years Old, Above 2 Years 5Old), Form (Feed Additives, Tablet, Oral Suspension) Players and Region - Global Market ...
$ 3500
Pharmacy Benefit Management Services Comprehensive Study by Type (Commercial Health Plans, Self-Insured Employer Plans, Medicare Part D Plans, Federal Employees Health Benefits Program, State Governm...
$ 3750
Levonorgestrel API Comprehensive Study by Type (Innovative API, Generic API), Application (Birth Control, Hormone Therapy), Drugs Type (Prescription Drugs, Over-the-counter Drugs), Grade (BP (British...
$ 3650
Blockchain in Pharmaceutical Comprehensive Study by Type (Public, Private, Consortium), Application (Supply Chain Management, Clinical Data Exchange and Interoperability, Drug Development, Clinical T...
$ 3450